Prevalence of overweight and obesity in patients with ulcerative colitis: a case-control study
https://doi.org/10.31146/1682-8658-ecg-212-4-6-11
Abstract
The incidence and prevalence of inflammatory bowel diseases (IBD) is growing in parallel with the obesity pandemic. The geography of the distribution of obesity and IBD on the planet have common features. In recent years, there has been information about the epidemiological interaction of predisposing factors to obesity and ulcerative colitis (UC). The aim of the study was to assess the prevalence of overweight and obesity in patients with UC in the Western Siberia region. Materials and methods: a case-control study of 165 ulcerative colitis was conducted in 56 healthy volunteers of comparable gender and age. Body mass index (BMI) was calculated using the formula: weight (kg)/weight (m2). Results: only in 7.9% of patients with UC BMI corresponded to a lack of body weight, in 48% BMI within normal parameters, in 43% of cases BMI corresponded to overweight and obesity. At the same time, the average values and median BMI in UC patients with acute and chronic course of the disease are close to the upper values of normal values. There are no gender differences in BMI compared to the control group. The BMI of patients with severe attack is significantly less than the BMI of patients with moderate attack. Hormonal dependence and resistance, the use of GIBP did not have a significant effect on the BMI of UC patients. In patients with UC, when compared with the control group, there are significantly more patients with type 2 diabetes mellitus. However, there was no significant relationship between the severity of the current attack among UC patients and the presence of type 2 diabetes mellitus in them. When comparing the group of patients with UC with the control group, there were no significant differences in the frequency of occurrence of NAFLD, cholelithiasis, coronary heart disease, arterial hypertension, while in patients with continuously recurrent UC, liver damage characteristic of NAFLD is significantly more common.
About the Authors
G. R. Bikbavova
Omsk State Medical University
Russian Federation
Russian Federation
M. A. Livzan
Omsk State Medical University
Russian Federation
Russian Federation
N. S. Lisyutenko
Omsk State Medical University
Russian Federation
Russian Federation
O. V. Martynenko
Regional Clinical Hospital
Russian Federation
Russian Federation
A. V. Indutny
Omsk State Medical University
Russian Federation
Russian Federation
References
1. Ramos G., Papadakis K. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin. Proc. 2019 Jan;94(1):155-165. doi: 10.1016/j.mayocp.2018.09.013.
2. GBD2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. doi: 10.1016/S2468-1253(19)30333-4.
3. Kaplan G. G., Ng S. C. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017 Feb;152(2):313-321.e2. doi: 10.1053/j.gastro.2016.10.020.
4. Maev I.V., Shelygin Yu.A., Skalinskaya M. I. et al. The Pathomorphosis of Inflammatory Bowel Diseases. Annals of the Russian Academy of Medical Sciences. 2020;75(1):27-35. doi: 10.15690/vramn1219.@@ Маев И. В., Шелыгин Ю. А., Скалинская М. И. и соавт. Патоморфоз воспалительных заболеваний кишечника. Вестник РАМН. 2020;75(1):27-35. doi: 10.15690/vramn1219.
5. Bernstein C. N., Rawsthorne P., Cheang M. et al. A population-based case control study of potential risk factors for IBD. Am. J. Gastroenterol. 2006 May;101(5):993-1002. doi: 10.1111/j.1572-0241.2006.00381.x.
6. Bischoff S.C., Barazzoni R., Busetto L., Campmans-Kuijpers M. et al. European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline. United European Gastroenterol J. 2022 Sep;10(7):663-720. doi: 10.1002/ueg2.12280.
7. Johnson AM, Loftus EV. Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD. Saudi J Gastroenterol. 2021 Jul-Aug;27(4):183-190. doi: 10.4103/sjg.sjg_30_21.
8. Garvey W. T., Garber A. J., Mechanick J. I. et al. On behalf of the AACE obesity scientific C. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014 Sep;20(9):977-89. doi: 10.4158/EP14280.PS.
9. Fink C., Iordanes K., Bakirtzi K. et al. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 2012 Aug;18(8):1550-7. doi: 10.1002/ibd.22893.
10. Versini M., Jeandel P. Y., Rosenthal E. et al. Obesity in autoimmune diseases: Not a passive bystander. Autoimmunity Rev. 2014 Sep;13(9):981-1000. doi: 10.1016/j.autrev.2014.07.001.
11. Kinlen D., Cody D., O’Shea D.Complications of obesity. QJM. 2018 Jul 1;111(7):437-443. doi: 10.1093/qjmed/hcx152.
12. Livzan M. A., Krolevets T. S., Lapteva I. V., Cherkashchenko N. A. Non-alcoholic fatty liver disease in persons with abdominal type of obesity. Evidence-based Gastroenterology. 2014, No.4, pp. 8-14. doi: 10.17116/dokgastro2014348-14.@@ Ливзан М. А., Кролевец Т. С., Лаптева И. В., Черкащенко Н. А. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология. -2014, -№.4, -С. 8-14. doi: 10.17116/dokgastro2014348-14.
13. Yorulmaz, E., Adali, G., Yorulmaz, H. et al. Metabolic syndrome frequency in inflammatory bowel diseases. Saudi J. Gastroenterol. 2011 Nov-Dec;17(6):376-82. doi: 10.4103/1319-3767.87177.
14. Zamani, M., Alizadeh-Tabari S., Singh S. et al. Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2022 Apr;55(8):894-907. doi: 10.1111/apt.16879.
15. Noorian S., Jeon Y., Nguyen M. T. et al. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. Inflamm. Bowel Dis. 2022 Jun 3;28(6):878-887. doi: 10.1093/ibd/izab199.
16. Lees C.W., Barrett J. C., Parkes M., Satsangi J. New IBD genetics: Common pathways with other diseases. Gut 2011, 60, 1739-1753. doi: 10.1136/gut.2009.199679
17. Sang MM, Sun ZL, Wu TZ. Inflammatory bowel disease and diabetes: Is there a link between them? World J Diabetes. 2022 Feb 15;13(2):126-128. doi: 10.4239/wjd.v13.i2.126.
18. Rodriguez-Duque J.C., Calleja J. L., Iruzubieta P. et al. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. Clin. Gastroenterol. Hepatol. 2023 Feb;21(2):406-414.e7. doi: 10.1016/j.cgh.2022.01.039.
19. Clinical recommendations “Ulcerative colitis”, 2020, developer of clinical recommendations Russian Gastroenterological Association; Association of Coloproctologists of Russia. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation.@@ Клинические рекомендации «Язвенный колит», 2020, разработчик клинических рекомендаций Российская гастроэнтерологическая ассоциация; Ассоциация колопроктологов России. Одобрено Научно-практическим Советом Миннздрава РФ.
Review
For citations:
Bikbavova G.R., Livzan M.A., Lisyutenko N.S., Martynenko O.V., Indutny A.V. Prevalence of overweight and obesity in patients with ulcerative colitis: a case-control study. Experimental and Clinical Gastroenterology. 2023;(4):6-11. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-212-4-6-11
Views:
252
Email this article 